Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis

Table 5 The meta-analysis of safety

Type of adverse events	No. of studies included	No. of cases (T/C)	Heterogeneity test		Meta-analysis results
Type of adverse events	No. of studies included	No. of cases (T/C)	P	I²	RR (95% CI)	P value
Comparison between exenatide versus metformin
Diarrhea	2	61/61	0.64	0%	0.11(0.01,0.84)	0.03
Nausea	3	106/94	0.58	0%	1.17(0.58,2.34)	0.66
Vomiting	3	106/94	0.85	0%	1.42(0.48,4.17)	0.52
Stomach pain	2	61/61	0.82	0%	0.25(0.03,2.17)	0.21
Constipation	2	61/61	0.82	0%	0.25(0.03,2.17)	0.21
Headache	2	65/53	0.84	0%	0.79(0.21,3.01)	0.73
Fatigue	2	61/61	0.14	55%	0.99(0.04,23.27)	1
Comparison between exenatide + metformin and metformin alone
Diarrhea	2	45/45	0.27	19%	0.65(0.35,1.21)	0.17
Nausea	2	45/45	0.24	29%	1.43(0.83,2.46)	0.2
Vomiting	2	45/45	0.45	0%	1(0.27,3.76)	1
Stomach pain	2	45/45	0.82	0%	0.25(0.03,2.16)	0.21
constipation	2	45/45	0.7	0%	1.5(0.26,8.56)	0.65
Headache	2	45/45	0.37	0%	1(0.18,5.54)	1
Fatigue	2	45/45	0.45	0%	1(0.27,3.76)	1

ISSN: 1472-6823